Business Description
Spyre Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00773J1034
Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21.1 | |||||
| 3-Year EPS without NRI Growth Rate | 18.6 | |||||
| 3-Year FCF Growth Rate | 27.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 38.04 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.98 | |||||
| 9-Day RSI | 42.4 | |||||
| 14-Day RSI | 45.94 | |||||
| 6-1 Month Momentum % | -22.3 | |||||
| 12-1 Month Momentum % | 134.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.7 | |||||
| Quick Ratio | 19.7 | |||||
| Cash Ratio | 19.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -165.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -17654.97 | |||||
| ROE % | -360.57 | |||||
| ROA % | -54.18 | |||||
| ROIC % | -388.58 | |||||
| 3-Year ROIIC % | 467.85 | |||||
| ROC (Joel Greenblatt) % | -3840.08 | |||||
| ROCE % | -64.41 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 215.82 | |||||
| PB Ratio | 6.45 | |||||
| Price-to-Tangible-Book | 6.45 | |||||
| EV-to-EBIT | -7.19 | |||||
| EV-to-EBITDA | -7.19 | |||||
| EV-to-Revenue | 1403.67 | |||||
| EV-to-Forward-Revenue | 18.54 | |||||
| EV-to-FCF | -7.95 | |||||
| Price-to-Net-Current-Asset-Value | 6.45 | |||||
| Price-to-Net-Cash | 3.87 | |||||
| Earnings Yield (Greenblatt) % | -13.91 | |||||
| FCF Yield % | -11.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SYRE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spyre Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.886 | ||
| EPS (TTM) ($) | -13.152 | ||
| Beta | 3.62 | ||
| Volatility % | 82.32 | ||
| 14-Day RSI | 45.94 | ||
| 14-Day ATR ($) | 1.885525 | ||
| 20-Day SMA ($) | 28.7585 | ||
| 12-1 Month Momentum % | 134.69 | ||
| 52-Week Range ($) | 8.43 - 47.97 | ||
| Shares Outstanding (Mil) | 50.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spyre Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spyre Therapeutics Inc Frequently Asked Questions
What is Spyre Therapeutics Inc(SYRE)'s stock price today?
The current price of SYRE is $27.76. The 52 week high of SYRE is $47.97 and 52 week low is $8.43.
When is next earnings date of Spyre Therapeutics Inc(SYRE)?
The next earnings date of Spyre Therapeutics Inc(SYRE) is 2024-11-08 Est..
Does Spyre Therapeutics Inc(SYRE) pay dividends? If so, how much?
Spyre Therapeutics Inc(SYRE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers